Roche to withdraw 2 Parkinson’s drugs from Korean market

Korea Biomedical Review

27 August 2021 - Roche said it would withdraw Parkinson’s syndrome treatment Madopar 125 mg and 250 mg tablets from the Korean market, after 30 years of the drug sales since the local marketing approval in 1992.

The company announced that it would voluntarily withdraw the permit for Madopar (levodopa 200 mg/benserazide 50 mg tablets) and discontinue the domestic supply after 31 December 2021.

Read Korea Biomedical Review article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , Market access , Korea